Agile Therapeutics, Inc. (AGRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Agile Therapeutics, Inc. (AGRX) trades at $1.51 with AI Score 59/100 (Grade B). Agile Therapeutics, Inc. is a women's healthcare company focused on developing and commercializing prescription contraceptive products. Market cap: $10.43M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for AGRX: AGRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AGRX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AGRX: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Agile Therapeutics, Inc. (AGRX) Healthcare & Pipeline Overview
Agile Therapeutics, Inc. is a women's healthcare company specializing in prescription contraceptive products, primarily the Twirla patch. With a focus on innovation and addressing unmet needs, Agile is developing line extensions to offer women more choices in managing their reproductive health within the specialty and generic drug market.
What Is the Investment Thesis for AGRX?
Agile Therapeutics presents a focused investment opportunity within the women's healthcare sector, centered on its Twirla contraceptive patch and pipeline of line extensions. The company's gross margin of 54.2% indicates potential profitability as sales scale. Growth catalysts include successful commercialization of Twirla and positive clinical trial results for its pipeline products like AG200-15 ER and SmP. However, potential risks include competition from established contraceptive methods, regulatory hurdles, and the need for additional financing, given the company's negative profit margin of -73.8%. The company's beta of 1.58 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
AGRX Key Highlights
- Market capitalization of $10.43M indicates a small-cap company with potential for growth but also higher risk.
- Gross margin of 54.2% suggests a strong pricing power and efficient cost management in producing Twirla.
- Profit margin of -73.8% highlights the company's current unprofitability, requiring close monitoring of operating expenses and revenue growth.
- Beta of 1.58 indicates higher volatility compared to the overall market, potentially offering higher returns but also greater risk.
- Lead product Twirla offers a differentiated contraceptive option in the form of a once-weekly patch.
Who Are AGRX's Competitors?
AGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRGO Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions. The company | $11.16 | +1.32% | $1.54B | 44 |
| BAYRY Bayer AG | $14.56 | -4.11% | $57.24B | 51 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AGRX's Key Strengths?
- Innovative transdermal patch technology.
- Focus on women's health and contraception.
- Pipeline of line extensions.
- Established brand with Twirla.
What Are AGRX's Weaknesses?
- Limited product portfolio.
- Reliance on Twirla sales.
- Negative profit margin.
- Small market capitalization.
What Could Drive AGRX Stock Higher?
- Potential FDA approval of Twirla line extensions (AG200-15 ER, SmP).
- Expansion of Twirla sales and market share.
- Strategic partnerships to expand geographic reach.
What Are the Key Risks for AGRX?
- Financial-distress signal — its Altman Z-Score of -41.24 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established contraceptive methods.
- Regulatory setbacks for pipeline products.
- Need for additional financing.
- Product liability risks.
What Are the Growth Opportunities for AGRX?
- Expansion of Twirla Market Share: Agile has the opportunity to increase Twirla's market share within the U.S. contraceptive market. This can be achieved through targeted marketing campaigns, improved patient education, and strategic partnerships with healthcare providers. The U.S. contraceptive market is estimated to be worth billions of dollars annually, providing a significant opportunity for Agile to grow its revenue base. Timeline: Ongoing.
- Successful Development and Commercialization of Pipeline Products: Agile's pipeline of Twirla line extensions, including AG200-15 ER and SmP, represents a significant growth opportunity. Positive clinical trial results and successful commercialization of these products could expand Agile's product portfolio and address a wider range of patient needs. The market for extended-cycle and low-dose contraceptives is growing, driven by patient demand for more convenient and personalized options. Timeline: 2027-2029.
- Strategic Partnerships and Licensing Agreements: Agile can pursue strategic partnerships and licensing agreements to expand its geographic reach and product offerings. Collaborating with larger pharmaceutical companies or regional distributors could accelerate the commercialization of Twirla and its pipeline products in international markets. Licensing agreements for complementary women's health products could also diversify Agile's revenue streams. Timeline: Ongoing.
- Focus on Patient Adherence and Compliance: Improving patient adherence and compliance with Twirla is crucial for driving sales growth. Agile can implement patient support programs, develop educational materials, and leverage digital health technologies to enhance patient engagement and adherence. Increased adherence leads to better contraceptive efficacy and higher customer retention rates. Timeline: Ongoing.
- Expansion into Adjacent Women's Health Markets: Agile can explore opportunities to expand into adjacent women's health markets, such as hormone therapy or fertility treatments. Leveraging its expertise in transdermal drug delivery and its existing relationships with healthcare providers, Agile can diversify its product portfolio and address a broader range of women's health needs. The women's health market is a large and growing market, offering numerous opportunities for Agile to expand its business. Timeline: 2030+
What Opportunities Does AGRX Have?
- Expansion of Twirla market share.
- Successful commercialization of pipeline products.
- Strategic partnerships and licensing agreements.
- Expansion into adjacent women's health markets.
What Threats Does AGRX Face?
- Competition from established contraceptive methods.
- Regulatory hurdles.
- Patent expirations.
- Product liability risks.
What Are AGRX's Competitive Advantages?
- Proprietary transdermal patch technology for drug delivery.
- Established brand recognition with Twirla.
- Pipeline of line extensions to expand product offerings.
- Relationships with healthcare providers and distributors.
What Does AGRX Do?
Agile Therapeutics, Inc., founded in 1997 and headquartered in Princeton, New Jersey, is a women's healthcare company dedicated to researching, developing, and commercializing innovative prescription contraceptive products. The company's flagship product is Twirla (AG200-15), a once-weekly transdermal patch that delivers a combination of ethinyl estradiol and levonorgestrel. Twirla provides women with a convenient and discreet method of contraception, offering an alternative to daily oral pills. Agile's mission is to expand contraceptive options and improve women's reproductive health outcomes. Beyond Twirla, Agile is actively developing a pipeline of line extensions, including AG200-15 Extended Regimen (ER), designed to reduce the frequency of withdrawal bleeding to four times per year. Other pipeline products include AG200-15 smaller patch (SmP) aimed at providing shorter, lighter withdrawal bleeds and potentially enhancing contraceptive efficacy, AG200-15 ER SmP combining extended regimen with a smaller patch, and P-Patch, a progestin-only contraceptive patch for women who cannot or prefer not to use estrogen-containing products. Agile operates primarily in the United States, focusing on commercializing and expanding the market reach of Twirla and its future product offerings.
What Products and Services Does AGRX Offer?
- Researches and develops prescription contraceptive products for women.
- Commercializes Twirla, a once-weekly contraceptive patch.
- Develops Twirla line extensions, including extended regimen and smaller patch variations.
- Aims to provide women with convenient and discreet contraceptive options.
- Focuses on addressing unmet needs in women's reproductive health.
- Seeks regulatory approvals for its products from the FDA.
How Does AGRX Make Money?
- Develops and manufactures prescription contraceptive products.
- Sells products directly to wholesalers and distributors.
- Generates revenue through product sales.
- Invests in research and development to expand its product pipeline.
What Industry Does AGRX Operate In?
Agile Therapeutics operates within the competitive specialty and generic drug manufacturing industry, specifically targeting the women's health market. The contraceptive market is characterized by diverse options, including oral pills, intrauterine devices (IUDs), implants, and transdermal patches like Twirla. The industry is influenced by factors such as evolving patient preferences, technological advancements, and regulatory changes. Agile competes with established pharmaceutical companies and generic manufacturers, requiring a focus on innovation, effective marketing, and strategic partnerships to gain market share. The demand for convenient and discreet contraceptive methods is a key market trend that Agile aims to capitalize on with its Twirla patch and pipeline products.
Who Are AGRX's Key Customers?
- Women seeking prescription contraception.
- Healthcare providers who prescribe contraceptive products.
- Wholesalers and distributors of pharmaceutical products.
- Pharmacies that dispense prescription medications.
Company Profile
Agile Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Alfred F. Altomari. AGRX has traded publicly since 2014.
How Agile Therapeutics, Inc. Is Valued
Agile Therapeutics, Inc. carries a market capitalization of $10.43M, placing it in the micro-cap category. Relative to its peer group, AGRX's quantitative score of 59/100 is roughly in line with the peer average of 63/100.
ROE 132%Key Financial Metrics
Return on equity for Agile Therapeutics, Inc. stands at 132.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -91.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.46 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Agile Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.24 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Agile Therapeutics, Inc. revenue of about $66.3M for fiscal 2026, with EPS near $1.70.
AGRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in AGRX's future, indicating that management believes in the company's potential.
- Community sentiment has shifted positively, with increased discussions around AGRX's innovative product pipeline attracting attention.
- Developments in their clinical trials have sparked optimism, with many investors seeing potential for breakthrough results.
- Market perception has improved due to strategic partnerships that enhance AGRX's credibility and reach in the industry.
Bear Case
- Concerns over regulatory hurdles persist, as previous delays in approvals have left some investors skeptical about the timeline for product launches.
- Community sentiment has shown signs of caution, with some traders expressing doubts about the sustainability of recent gains.
- Increased competition in the biotech space may dilute AGRX's market share, leading to bearish views among analysts.
- Recent earnings reports have raised questions about profitability and operational efficiency, causing some investors to reconsider their positions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
AGRX Latest News
-
Earnings Scheduled For November 9, 2023
benzinga · Nov 9, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Aug 9, 2023
-
Earnings Scheduled For August 9, 2023
benzinga · Aug 9, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 11, 2023
AGRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AGRX.
Price Targets
Wall Street price target analysis for AGRX.
AGRX MoonshotScore
What does this score mean?
The MoonshotScore rates AGRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Alfred F. Altomari
Chairman and Chief Executive Officer
Alfred F. Altomari has served as the Chairman and Chief Executive Officer of Agile Therapeutics since September 2016. He has extensive experience in the pharmaceutical and healthcare industries, with a proven track record of leading and growing companies. Prior to joining Agile, Mr. Altomari held leadership positions at several pharmaceutical companies, including as CEO of Agile Therapeutics, Inc. and various executive roles at Johnson & Johnson. He holds a B.S. in Pharmacy from the University of Rhode Island and an MBA from Rider University.
Track Record: Since becoming CEO, Alfred F. Altomari has focused on the commercialization of Twirla and the development of Agile's pipeline products. He has overseen the company's efforts to secure regulatory approvals, build its sales and marketing infrastructure, and establish partnerships with key stakeholders. Under his leadership, Agile has made progress in expanding access to Twirla and advancing its mission of providing women with innovative contraceptive options.
AGRX Healthcare Stock FAQ
What does Agile Therapeutics, Inc. do?
Agile Therapeutics, Inc. is a women's healthcare company focused on developing and commercializing prescription contraceptive products. Its primary product is Twirla, a once-weekly transdermal patch that delivers hormones for contraception. Agile's business model centers around researching, developing, and marketing innovative contraceptive options to address unmet needs in women's reproductive health. The company aims to provide women with convenient, discreet, and effective methods of contraception through its proprietary patch technology and pipeline of line extensions.
What do analysts say about AGRX stock?
Analyst coverage of Agile Therapeutics, Inc. (AGRX) is limited, reflecting its small market capitalization and early stage of commercialization. However, analysts generally focus on the potential of Twirla to gain market share in the competitive contraceptive market. Key valuation metrics include revenue growth, gross margin, and cash burn. Growth considerations center on the successful commercialization of Twirla, the development of pipeline products, and the company's ability to secure additional funding. Analyst ratings and price targets vary, reflecting differing opinions on the company's prospects.
What are the main risks for AGRX?
Agile Therapeutics faces several key risks, including competition from established contraceptive methods such as oral pills, IUDs, and implants. Regulatory risks include potential delays or rejections in the approval of pipeline products. Financial risks include the need for additional funding to support commercialization and research and development activities. Product liability risks are inherent in the pharmaceutical industry. The company's small size and limited product portfolio also increase its vulnerability to market fluctuations and competitive pressures.
What are the key factors to evaluate for AGRX?
Agile Therapeutics, Inc. (AGRX) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does AGRX data refresh on this page?
AGRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AGRX's recent stock price performance?
Agile Therapeutics, Inc. (AGRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative transdermal patch technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AGRX overvalued or undervalued right now?
Valuing Agile Therapeutics, Inc. (AGRX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AGRX?
Before investing in Agile Therapeutics, Inc. (AGRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial data is as of the most recent reporting period.